Business Insights, June 2010, Pages: 250
Background to HIV
Key development areas
Genomics and flavivirus infection
Background to flaviviruses
Key development areas
Genomics and hepatitisC
Background to hepatitisC
Key development areas
Datamonitor, June 2010, Pages: 108
A and B populations by age for the US, Japan, France, Germany, Italy, Spain and the UK (%)
Figure: Current hepatitisC and human immunodeficiency virus prevalence among hemophilia and general populations
Business Insights, Nov 2011, Pages: 168
testing market?
- Who is developingnew innovative products for the infectious disease MDx market and what paths to commercialization are they following?
- How are the different sectors of the infectious
Business Insights, June 2007, Pages: 244
also been made in the development of RNAi-based therapeutic products, bringing them significantly closer to the market.
‘Outlook for RNAi 2007’ is a new report which provides a detailed insight
Markets and Markets, Feb 2011, Pages: 264
and commercialization of new drugs through agreements and collaborations which therefore accounted for the highest share of the total competitive developments in the global top 10 drug delivery technologies market from
PharmaVision, July 2009, Pages: 225
This cutting edge & insightful report can be used to interpret & assess the potential of RNAi-based medicines. It provides opinions & market projections to:
- assess the commercial potential
Datamonitor, Dec 2009, Pages: 187
unmet need within the DLBCL and FL markets and identify opportunities for new product development
- Enhance commercial positioning by increasing understanding of current dynamics within the DLBCL and FL
Datamonitor, March 2008, Pages: 123
into HAART? 53
HepatitisC 54
Disease background 54
Targets for antibody development and pipeline overview 55
XTL-6865 58
Bavituximab 59
HuMax-HepC 59
IB-657 60
Other viral infections 60
Rabies 60
West Nile
Espicom Business Intelligence Ltd, April 2009, Pages: 450
infections
Human immunodeficiency virus (HIV)
HepatitisB (HBV)
HepatitisC (HCV)
Herpes
Current treatments
Bacterial infection
Table 4 Top ten antibiotics worldwide (based on 2007 sales)
Figure 9 US
Elsevier Science and Technology, Dec 2003, Pages: 598
in chimpanzees (C.M. Walker).
6. Adoptive immune transfer as a therapeutic approach for persistent hepatitisB virus infection (D. Shouval).
7. Perspectives in HCV vaccine development (E. Depla).
Viral
